

## ELIXIR MD™ Secures First and Only FDA Clearance For Soft Tissue Coagulation For LED Light Therapy in Plastic Surgery

IRVINE, CA, USA, July 28, 2024 /EINPresswire.com/ -- ELIXIR MD<sup>™</sup>, a global leader in photobiomodulation technology, has achieved a major milestone in the field of plastic surgery. The company is proud to announce that its revolutionary technology, (EPBM<sup>™</sup>), has received FDA 510(k) clearance for use in general and plastic surgery procedures. This makes ELIXIR MD<sup>™</sup> the first and only company to receive such clearance for an LED light therapy device in the plastic surgery industry.

The FDA clearance is a significant achievement for ELIXIR MD<sup>™</sup> and a testament to the safety and effectiveness of its EPBM<sup>™</sup> technology. This clearance allows plastic surgeons



to use ELIXIR MD<sup>™</sup> device in a variety of procedures. The EPBM<sup>™</sup> technology utilizes specific wavelengths of light to stimulate cellular activity, promoting healing and reducing inflammation, pain, and scarring.

"ELIXIR MD<sup>™</sup> is committed to investing in R&D to provide plastic surgeons with the advancements they need to deliver the highest quality of care and achieve the fastest post-surgery results," said Ewan Yassen, CEO of ELIXIR MD<sup>™</sup>. "The new indication for soft tissue coagulation for LED light therapy in plastic surgery enhances the product's intended use, helping practitioners expand their patient base."

Since its inception, ELIXIR MD<sup>™</sup> has been gaining widespread global brand awareness, with more than 70 plastic surgeons using the system worldwide. The ELIXIR MD<sup>™</sup> brand is poised to become the new standard in plastic surgery for post-op recovery solutions.

## About ELIXIR MD™

ELIXIR MD<sup>™</sup> is at the forefront of medical innovation, dedicated to enhancing well-being and delivering impressive results. Specializing in Photobiomodulation Devices, our unique EPBM<sup>™</sup> technology is designed to support Plastic Surgeons in enhancing surgical procedures and reducing recovery times. Our cutting-edge technology positions us strongly in the multi-billion dollar market, spanning various surgical specialties including plastic surgery and ENT. For more information about ELIXIR MD<sup>™</sup> and its technology, visit <u>www.elixir-md.com</u>.

Michael Elias ELIXIR MD™ +1 949-695-7727 email us here Visit us on social media: Facebook X LinkedIn Instagram YouTube

This press release can be viewed online at: https://www.einpresswire.com/article/731045814

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.